This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations
1 Citations
Facts about Cadherin-6.
.
Human | |
---|---|
Gene Name: | CDH6 |
Uniprot: | P55285 |
Entrez: | 1004 |
Belongs to: |
---|
No superfamily |
cadherin 6, type 2, K-cadherin (fetal kidney); cadherin, fetal kidney; Cadherin6; Cadherin-6; CDH6; KCAD; K-cadherin (fetal kidney); K-Cadherin
Mass (kDA):
88.309 kDA
Human | |
---|---|
Location: | 5p13.3 |
Sequence: | 5; NC_000005.10 (31193686..31329146) |
Highly expressed in brain, cerebellum, and kidney. Lung, pancreas, and gastric mucosa show a weak expression. Also expressed in certain liver and kidney carcinomas.
Cell membrane; Single-pass type I membrane protein.
The CDH6 marker is a paralog to CDH9 can promote metastasis and invasion of NPC. It is also used to determine metastatic OS and can be quantified with ELISA. Boster Bio offers product credits to researchers worldwide for the use of CDH6. Here's how it works.
The human genome is home to the cadherin-6 gene. It is a paralog to CDH9. The corresponding variant is a transcript with a greater size and isoform. This gene could be a key factor in the classification of different cell types. It is prominently expressed in the pancreas as well as the brain. However it isn't well expressed in other tissues. It is not expressed in the pancreas and gastric mucosa and pancreatic.
The significance of cathepsin D in the invasive capabilities of NPC cells has been studied. The cells were co-cultured with lethally irradiated CNE1 cells and inducing them to move. Their supernatant had elevated levels of Slit2, suggesting that the inflammatory response to lethal radiation might enhance cell migration. CNE1 cells were also able of inhibiting liver and lung metastasis by suppressing Slit2.
MiR-26a regulates nasopharyngeal metastasis from cancer. The up-regulation of miR-205-5p in the exosomal region was associated with poorer overall survival among NPC patients. Inhibition prevented the formation of tubes, but overexpression of miR205-5p promoted it. Furthermore, miR205-5p facilitates the formation of tubes in NPC cells.
Although it isn't evident what NogoB does in NPC However, these results suggest that it may be a good biomarker to help determine the prognosis. Nogo-B activating RhoA's SRF-MRTFA pathway can increase metastasis and invasion in NPC patients. These results suggest that CCG-1423 is an important target drug for Nogo-B-overexpressing NPC patients.
Nasopharyngeal carcinoma is a prevalent epithelial malignancy. It is prevalent in Southeast Asia, Southern China and the Mediterranean basin. NPC is closely linked to the Epstein-Barr virus which is a major cause of the poor prognosis of the disease.
The expression of Nectin-3 in the GSE12452 dataset was inverted connected to the expression level of ZNF582, suggesting Nectin-3 might be an oncogene that is present in NPC. Nectin-3 promoted metastasis and invasion of NPC cells when overexpressed in cells. These functions were inhibited by Nectin-3 knockdown.
LncRNAs are involved in various types of cancer. ANRIL, 3834-nt RNA encoded by 19 exons in antisense increased NPC cell growth and modified glucose metabolism. It also induced the formation a side population stem-like cancer cells. NPC cells were able block MEG3 and, consequently, induce apoptosis and improved radiosensitivity. Its exact role in NPC remains unclear.
Osteosarcoma is the most frequent bone cancer that is a primary malignant. It is associated with high rates of expansion, recurrence, as well as death. Despite advancements in surgery and adjuvant therapy, the disease has a low survival rate. About half of OS patients have recurrences in other organs such as the lungs. In these patients, controlling reccurrence is among the most difficult challenges.
Boster Bio CDH6 regulates the expression of POSTN epigenetic protein. This gene is involved in OS metastasis and invasion. This study provides an idea of how to identify OS biomarkers. Boster Bio recently announced a blood test to determine CDH6 expression in patients with metastatic OS. This test is a first step towards improving OS treatment.
The POSTN shRNA treatment significantly inhibited OC cells' invasion and movement. Additionally, it reduced PI3K, AKT, and p-AKT, three markers implicated in the progression of OS. The results also confirm the efficacy of Boster Bio CDH6 as a biomarker to detect metastatic OS.
The miR-223-3p-mRNA expression was related to overall survival (OS) in patients with ccRCC. CRC patients had a lower OS in the event that they had higher levels of miR-223-3p. A poor prognosis was also linked with miR-223-3p levels.
Boster Bio CDH6 is an ELISA which measures the protein's level. It is extremely sensitive and specific. CDH6 is a membrane protein that plays a vital role in homophilic cell-cell adhesion. The protein also plays multiple functions in the process of cell differentiation. Studies have demonstrated that lower levels of CDH6 protein may contribute to the growth of tumors.
PMID: 7743525 by Shimoyama Y., et al. Isolation and sequence analysis of human cadherin-6 complementary DNA for the full coding sequence and its expression in human carcinoma cells.
PMID: 2059658 by Suzuki S., et al. Diversity of the cadherin family: evidence for eight new cadherins in nervous tissue.
*More publications can be found for each product on its corresponding product page